COVID-19 respiratory mucosal DNA vaccine is effective in mice

Mucosal vaccination through mucus membranes provides strong protection
against SARS-CoV-2 infection.
Immune cells in the nose and lungs are thought to better defend against and block the virus
that causes COVID-19.
An international team of researchers has just demonstrated that its mucosal DNA vaccine is able to ensure the overall survival of a group of mice infected with a version of the virus adapted to the species, which in turn kills 100% of the unvaccinated mice.
Made by a vector developed by a researcher at the Laboratory of Immunotherapy Immunology and New Concepts at the French National Center for Scientific Research, the vaccine works in a similar way to RNA vaccines on the market: the vector delivers DNA viruses into target cells, causing them to produce a SARS-CoV-2 protein and allowing the immune system to prepare itself
by producing antibodies and lymphocytes to fight the virus 。 The study, which did not measure the effectiveness of the vaccine for transmission between mice, was published in The Lancet's Biomaterials.
However, scientists hope that vaccination methods based on this principle can complement current strategies and perhaps provide better protection
against transmission.

1.
Each group of tested mice consists of
10.

2.
A carrier is an element derived from medicinal chemistry that delivers molecules
in a targeted manner.
Here, the vector is a synthetic nanoparticle whose properties allow it to penetrate the mucosa and introduce DNA encoding viral proteins into the cells of
the respiratory system.